{"id":947884,"date":"2026-03-31T08:47:17","date_gmt":"2026-03-31T12:47:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/"},"modified":"2026-03-31T08:47:17","modified_gmt":"2026-03-31T12:47:17","slug":"inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/","title":{"rendered":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">JENA, Germany, March  31, 2026  (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Raymond James 2026 Biotech Innovation Symposium<\/strong><br \/>\n        <br \/>April 14, 2026, in New York, NY<br \/>The Company will hold one-on-one investor meetings.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>About InflaRx<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2018s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK\/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.<\/p>\n<p align=\"justify\">InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U7I25O1cPNGBMVP5BeP1yA5b2jZOPdzHxJs6gCiIChOn4z5NtG37OD4eq6FLL8zzkyeCxPWCIj6uxMj_qUlKhw==\" rel=\"nofollow\" target=\"_blank\"><u>www.inflarx.de<\/u><\/a>. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>InflaRx N.V.<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>MC Services AG<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Jan Medina, CFA<br \/>Vice President, Head of Investor Relations<br \/>Email: <a href=\"mailto:IR@inflarx.de\" rel=\"nofollow\" target=\"_blank\"><u>IR@inflarx.de<\/u><\/a><\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Katja Arnold, Laurie Doyle, Dr. Regina Lutz<br \/>Email: <a href=\"mailto:inflarx@mc-services.eu\" rel=\"nofollow\" target=\"_blank\"><u>inflarx@mc-services.eu<\/u><\/a><br \/>Europe: +49 89-210 2280<br \/>U.S.: +1-339-832-0752<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>FORWARD-LOOKING STATEMENTS<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cbelieve,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue,\u201d among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading \u201cRisk factors\u201d and \u201cCautionary statement regarding forward looking statements\u201d in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjM2YzhjZTYtZGE4Mi00MjBlLWJiOTktNjcyM2M0MjhiNjVkLTEyMDU3OTQtMjAyNi0wMy0zMS1lbg==\/tiny\/InflaRx-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation Symposium April 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2018s lead program is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-947884","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation Symposium April 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2018s lead program is &hellip; Continue reading &quot;InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T12:47:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium\",\"datePublished\":\"2026-03-31T12:47:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/\"},\"wordCount\":487,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/\",\"name\":\"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\",\"datePublished\":\"2026-03-31T12:47:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/","og_locale":"en_US","og_type":"article","og_title":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","og_description":"JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) &#8212; InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation Symposium April 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2018s lead program is &hellip; Continue reading \"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-31T12:47:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium","datePublished":"2026-03-31T12:47:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/"},"wordCount":487,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/","name":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=","datePublished":"2026-03-31T12:47:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4MTUzNyM3NTEyMzM4IzIxOTQyNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-participation-in-the-raymond-james-2026-biotech-innovation-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=947884"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=947884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=947884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=947884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}